Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 131-138

  Meuwese, Christiaan L ^a,b   Dekker, Friedo W ^a   Lindholm, Bengt ^b   Qureshi, Abdul R ^b   Heimburger, Olof ^b   Barany, Peter ^b   Stenvinkel, Peter ^b   Carrero, Juan J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIANEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEVOTHYROXINE; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTHYROIDISM; KAPLAN MEIER METHOD; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SMOKING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

AGED; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 84857097187     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05250511     Document Type: Article

References (33)

1. Warner MH, Beckett GJ: Mechanisms behind the non-thyroidal illness syndrome: An update. J Endocrinol 205: 1-13, 2010
2. Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriquez HJ, Massry SG: The thyroid in end-stage renal disease. Medicine (Baltimore) 67: 187-197, 1988
3. Lim VS, Fang VS, Katz AI, Refetoff S: Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. J Clin Invest 60: 522-534, 1977
4. Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS: The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant 24: 1534-1538, 2009
5. Ozen KP, Asci G, Gungor O, Carrero JJ, Kircelli F, Tatar E, Sevinc Ok E, Ozkahya M, Toz H, Cirit M, Basci A, Ok E: Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 33: 305-312, 2011
6. Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G: Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1296-1300, 2008
7. Lo JC, Chertow GM, Go AS, Hsu CY: Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 67: 1047-1052, 2005
8. Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F: Low triiodothyronine: A new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 16: 2789-2795, 2005
9. Iglesias P, Díez JJ: Thyroid dysfunction and kidney disease. Eur J Endocrinol 160: 503-515, 2009
10. Chopra IJ: Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract 2: 45-52, 1996
11. Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C: Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease.Am J Nephrol 33: 25-32, 2011
12. Tatar E, Kircelli F, Asci G, Carrero JJ, Gungor O, Demirci MS, Ozbek SS, Ceylan N, Ozkahya M, Toz H, Ok E: Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 6: 2240-2246, 2011
13. Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino LS, Bonanno G, Seminara G: Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens 24: 2039-2046, 2006
14. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P: Low triiodothyronine and survival in end-stage renal disease. Kidney Int 70: 523-528, 2006
15. Fernández-Reyes MJ, Diez JJ, Collado A, Iglesias P, Bajo MA, Estrada P, Del Peso G, Heras M, Molina A, Selgas R: Are low concentrations of serum triiodothyronine a good marker for long-term mortality in hemodialysis patients? Clin Nephrol 73: 238-240, 2010
16. Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, Bárány P, Heimbürger O, Suliman ME, Alvestrand A, Lindholm B, Stenvinkel P: Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 262: 690-701, 2007
17. Enia G, Panuccio V, Cutrupi S, Pizzini P, Tripepi G, Mallamaci F, Zoccali C: Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 22: 538-544, 2007
18. Andersen S, Pedersen KM, Bruun NH, Laurberg P: Narrow individual variations in serum T(4) and T(3) in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87: 1068-1072, 2002
19. Karmisholt J, Andersen S, Laurberg P: Variation in thyroid function in subclinical hypothyroidism: Importance of clinical follow-up and therapy. Eur J Endocrinol 164: 317-323, 2011
20. Snaedal S, Heimbürger O, Qureshi AR, Danielsson A, Wikström B, Fellström B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Bárány P: Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: Implications for patient survival. Am J Kidney Dis 53: 1024-1033, 2009
21. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Bárány P, Snaedal-Jonsdottir S, Alvestrand A, Heimbürger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 85: 695-701, 2007
22. Davies SJ, Phillips L, Naish PF, Russell GI: Quantifying co-morbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 17: 1085-1092, 2002
23. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, Barany P, Heimburger O, Lindholm B, Krediet RT, Boeschoten EW, Carrero JJ: Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-a are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26: 1313-1318, 2011
24. Friedman AN, Fadem SZ: Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 21: 223-230, 2010
25. de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW Netherlands Cooperative Study on the Adequacy of Dialysis-II Study Group: Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 19: 127- 135, 2009
26. Fukuyama K, Ichiki T, Takeda K, Tokunou T, Iino N, Masuda S, Ishibashi M, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A: Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41: 598-603, 2003
27. Costantini F, Pierdomenico SD, De Cesare D, De Remigis P, Bucciarelli T, Bittolo-Bon G, Cazzolato G, Nubile G, Guagnano MT, Sensi S, Cuccurullo F, Mezzetti A: Effect of thyroid function on LDL oxidation. Arterioscler Thromb Vasc Biol 18: 732-737, 1998
28. Fukuyama K, Ichiki T, Imayama I, Ohtsubo H, Ono H, Hashiguchi Y, Takeshita A, Sunagawa K: Thyroid hormone inhibits vascular remodeling through suppression of cAMP response element binding protein activity. Arterioscler Thromb Vasc Biol 26: 2049-2055, 2006
29. McLarty DG, Ratcliffe WA, McColl K, Stone D, Ratcliffe JG: Letter: Thyroid-hormone levels and prognosis in patients with serious non-thyroidal illness. Lancet 2: 275-276, 1975
30. Slag MF, Morley JE, Elson MK, Crowson TW, Nuttall FQ, Shafer RB: Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 245: 43-45, 1981
31. Hafeman DM, Schwartz S: Opening the black box: A motivation for the assessment of mediation. Int J Epidemiol 38: 838-845, 2009
32. Takamura N, Akilzhanova A, Hayashida N, Kadota K, Yamasaki H, Usa T, Nakazato M, Maeda T, Ozono Y, Aoyagi K: Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 204: e77-e81, 2009
33. Kruger TE: Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Adv Neuroimmunol 6: 387-395, 1996